{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:08:47Z","timestamp":1773248927561,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Patients with membranous nephropathy and kidney insufficiency have an extremely high risk of progression to end-stage renal disease. Whether rituximab can effectively treat membranous nephropathy patients with renal dysfunction remains unknown at present. The aim of our study was to evaluate the effectiveness and safety of rituximab (RTX) in membranous nephropathy with kidney insufficiency.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively analyzed the clinical data of 35 membranous nephropathy patients with kidney insufficiency administered in the First Affiliated Hospital of Zhengzhou University between January 2020 and December 2021. Patients were followed every 1\u20133\u00a0months for a total of 6 months. Clinical data were collected including anti-phospholipase A2 receptor antibody (anti-PLA2R antibody) quantification, 24-h urinary protein, serum albumin, and serum creatinine. The percentage of patients who achieved clinical remission was measured.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> There were 7 (20%) patients who achieved complete or partial response at 6\u00a0months after RTX treatment. After 6 months of treatment, patients were clinically improved as evidenced by significant improvements in anti- PLA2R antibody titer [7.70 (5.72, 16.72) vs. 59.20 (17.70, 187.50)\u00a0RU\/ml, <jats:italic>p<\/jats:italic> &amp;lt; 0.001], 24-h urine protein [7.04 (4.43, 8.90) vs. 10.15 (4.83, 13.57) g\/d, <jats:italic>p<\/jats:italic> &amp;lt; 0.001], serum albumin [30.55 (24.97, 33.27) vs. 21.40 (16.75, 25.00)g\/L, <jats:italic>p<\/jats:italic> &amp;lt; 0.001], serum creatinine [99.50 (75.25, 140.25) vs. 152.00 (134.50, 232.50)\u00a0\u00b5mol\/L, <jats:italic>p<\/jats:italic> = 0.022], and estimated glomerular filtration rate (eGFR) [78.29 (50.15, 101.55) vs. 41.12 (26.53, 51.41)\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.045]. There were no significantly differences between responders and nonresponders in the baseline levels of anti-PLA2R antibodies, proteinuria, serum albumin, and renal function. After the RTX treatment, anti-PLA2R antibodies turned negative in all responders, but the antibody level persisted maintained positive in all but 5 nonresponders. The patients who achieved response maintained a stable kidney function during the study period, with eGFR 29.03 (28.76, 35.07)\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> before rituximab treatment and 62.73 (62.34, 63.13)\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> at the end of follow-up (<jats:italic>p<\/jats:italic> = 0.053).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> RTX therapy might be an alternative treatment in reducing proteinuria and maintaining stable renal function among membranous nephropathy patients even with kidney insufficiency.<\/jats:p>","DOI":"10.3389\/fphar.2022.1002117","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T14:58:53Z","timestamp":1665413933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Rituximab in patients with membranous nephropathy and kidney insufficiency"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanhong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ckj\/sfx105","article-title":"Low-dose rituximab therapy in resistant idiopathic membranous nephropathy: Single-center experience","volume":"11","author":"Bagchi","year":"2018","journal-title":"Clin. Kidney J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","author":"Branten","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","article-title":"Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency","volume":"91","author":"Branten","year":"1998","journal-title":"QJM Mon. J. Assoc. Physicians"},{"key":"B6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.7326\/0003-4819-114-9-725","article-title":"Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone","volume":"114","author":"Bruns","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"574997","DOI":"10.3389\/fimmu.2020.574997","article-title":"Th17-Immune response in patients with membranous nephropathy is associated with thrombosis and relapses","volume":"11","author":"Cremoni","year":"2020","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","article-title":"Cytotoxic therapy for membranous nephropathy and renal insufficiency: Improved renal survival but high relapse rate","volume":"19","author":"du Buf-Vereijken","year":"2004","journal-title":"Nephrol. Dial. Transpl."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy","volume":"46","author":"du Buf-Vereijken","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","article-title":"Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy","volume":"34","author":"Fenoglio","year":"2021","journal-title":"J. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: A journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425255.2017.1277205","article-title":"The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents","volume":"13","author":"Ghobadi","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ekir.2019.12.006","article-title":"Rituximab in patients with phospholipase A2 receptor-associated membranous nephropathy and severe CKD","volume":"5","author":"Hanset","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"B17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0272-6386(12)70204-4","article-title":"Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function","volume":"19","author":"Jindal","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J. Formos. Med. Assoc. = Taiwan yi zhi."},{"key":"B19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.intimp.2019.03.002","article-title":"Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis","volume":"70","author":"Liu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/ndt\/gfw251","article-title":"Low-dose rituximab is poorly effective in patients with primary membranous nephropathy","volume":"32","author":"Moroni","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nephro.2021.10.002","article-title":"Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies","volume":"18","author":"Ou","year":"2022","journal-title":"Nephrol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/0961203309360539","article-title":"Ocular side effects of anti-rheumatic medications: What a rheumatologist should know","volume":"19","author":"Peponis","year":"2010","journal-title":"Lupus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am. J. Transpl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.kint.2016.02.022","article-title":"Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy","volume":"89","author":"Ramachandran","year":"2016","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000518609","article-title":"Immunosuppressive therapy in primary membranous nephropathy with compromised renal function","volume":"146","author":"Ramachandran","year":"2022","journal-title":"Nephron"},{"key":"B26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in pla2r1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000506948","article-title":"New ways of understanding membranous nephropathy","volume":"144","author":"Trujillo","year":"2020","journal-title":"Nephron"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in pla2r-antibody-associated membranous nephropathy: Cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/ndt\/gfx295","article-title":"Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort","volume":"33","author":"Wang","year":"2018","journal-title":"Nephrol. Dial. Transpl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1002117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T14:58:54Z","timestamp":1665413934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1002117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":33,"alternative-id":["10.3389\/fphar.2022.1002117"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1002117","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"article-number":"1002117"}}